ASH 2018 - Chronic Lymphocytic Leukemia

ASH 2018 - Chronic Lymphocytic Leukemia

Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL

ASH 2018 - Chronic Lymphocytic Leukemia

ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry

ASH 2018 - Chronic Lymphocytic Leukemia

Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Frontline Ibrutinib Treatment Is Associated with Lower Total Cost of Care Compared with Chemoimmunotherapy in Patients with CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Improved MRD Response Rates with Ibrutinib and Obinutuzumab in Patients with CLL

ASH 2018 - Chronic Lymphocytic Leukemia

MURANO Study Explores Potential for Venetoclax-Rituximab Combination Therapy in Relapsed/Refractory CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-Up Efficacy and Safety from the iNNOVATE Study

ASH 2018 - Chronic Lymphocytic Leukemia

Dual Inhibition of Bruton’s Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

ASH 2018 - Chronic Lymphocytic Leukemia

Ibrutinib 7-Year Follow-Up Data in First-Line and Relapsed/Refractory Patients with CLL/SLL

1
2

Page 1 of 2
Results 1 - 10 of 19

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.